RESEARCH
Tumor mutational burden studied as prognostic marker in metastatic CRC receiving immunotherapyA retrospective cohort study of 221 metastatic CRC patients receiving anti-PD-1/PD-L1 immunotherapy plus chemotherapy assessed tumor mutational burden as a biomarker for survival and quality of life outcomes. (Medicine)